Manuscripts

View in Pubmed

Fluoxetine and its active metabolite norfluoxetine disrupt estrogen synthesis in a co-culture model of the feto-placental unit.
Hudon Thibeault AA, Laurent L, Vo Duy S, Sauvé S, Caron P, Guillemette C, Sanderson JT, Vaillancourt C.
Mol Cell Endocrinol. 2016 Nov 24;442:32-39. [Epub ahead of print] PubMed PMID: 27890559.

A Rare UGT2B7 Variant Creates a Novel N-Glycosylation Site at Codon 121 with Impaired Enzyme Activity.
Girard-Bock C, Benoit-Biancamano MO, Villeneuve L, Desjardins S, Guillemette C.
Drug Metab Dispos. 2016 Dec;44(12):1867-1871. PubMed PMID: 27612916.

Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, Chaturvedi AK, Hildesheim A, Berndt SI, Safaeian M, Pinto L, Wentzensen N.
Int J Cancer. 2017 Feb 1;140(3):600-610. PubMed PMID: 27770434; PubMed Central PMCID: PMC5159268.

Divergent Expression and Metabolic Functions of Human Glucuronosyltransferases through Alternative Splicing.
Rouleau M, Tourancheau A, Girard-Bock C, Villeneuve L, Vaucher J, Duperré AM, Audet-Delage Y, Gilbert I, Popa I, Droit A, Guillemette C. Cell Rep. 2016 Sep 27;17(1):114-24. PubMed PMID: 27681425.

Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.
Cornu JN, Audet-Walsh E, Drouin S, Bigot P, Valeri A, Fournier G, Azzouzi AR, Roupret M, Cormier L, Chanock S, Guillemette C, Cussenot O, Lévesque E, Cancel-Tassin G.
World J Urol. 2016 Jun 8. [Epub ahead of print] PubMed PMID: 27277477.

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C.
Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. Epub 2015 Dec 8. PubMed PMID: 26645279.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel S, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW.
Clin Pharmacol Ther. 2016 Apr;99(4):363-9. Epub 2015 Nov 9. Review.  PubMed PMID: 26417955.

Assay reproducibility of serum androgen measurements using liquid chromatography-tandem mass spectrometry.
Trabert B, Xu X, Falk RT, Guillemette C, Stanczyk FZ, McGlynn KA.
J Steroid Biochem Mol Biol. 2016 Jan;155 (Pt A):56-62. Epub 2015 Sep 28 PubMed PMID: 26416142.

Evidences of Biological Functions of Biliverdin Reductase A in the Bovine Epididymis.  D’Amours O, Frenette G, Caron P, Belleannée C, Guillemette C, Sullivan R.
J Cell Physiol. 2016 May;231(5):1077-89 Epub 2015 Sep 30.   PubMed PMID: 26395865.

Epigenetic Regulation of Steroid Inactivating UDP-Glucuronosyltransferases by microRNAs in Prostate Cancer.
Margaillan G, Lévesque É, Guillemette C.
J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):85-93.  Epub 2015 Sep 15. PubMed PMID: 26385605.

BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.
Wang ZQ, Faddaoui A, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Guillemette C, Gobeil S, Macdonald E, Vanderhyden B, Bachvarov D.
Oncotarget. 2015 Oct 13;6(31):31522-43  PubMed PMID: 26372729.

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, Cecchin E, Innocenti F, Toffoli G, Lévesque E, Guillemette C.
Pharmacogenet Genomics. 2015 Dec;25(12):573-83 PubMed PMID: 26352872.

A chromatography/tandem mass spectrometry method for the simultaneous profiling of ten endogenous steroids, including progesterone, adrenal precursors, androgens and estrogens, using low serum volume.
Caron P, Turcotte V, Guillemette C.
Steroids. 2015 Dec;104:16-24.  Epub 2015 Aug 6, PubMed PMID: 26254607.

The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.
Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E.
Eur Urol. 2016 Apr;69(4):601-9. Epub 2015 Jul 26.  PubMed PMID: 26215610.

Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.
Margaillan G, Rouleau M, Klein K, Fallon JK, Caron P, Villeneuve L, Smith PC, Zanger UM, Guillemette C.
Drug Metab Dispos. 2015 Sep;43(9):1331-5. Epub 2015 Jun 15. PubMed PMID: 26076694.

Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk.
Brinton LA, Key TJ, Kolonel LN, Michels KB, Sesso HD, Ursin G, Van Den Eeden SK, Wood SN, Falk RT, Parisi D, Guillemette C, Caron P, Turcotte V, Habel LA, Isaacs CJ, Riboli E, Weiderpass E, Cook MB.
J Clin Oncol. 2015 Jun 20;33(18):2041-50. Epub 2015 May 11. PubMed PMID: 25964249.

Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing.
Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Lévesque E, Droit A, Guillemette C.
Pharmacogenomics J. 2016 Feb;16(1):60-70. Epub 2015 Apr 14. PubMed PMID: 25869014.

A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.
Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Lévesque E, Guillemette C.
Pharmacogenomics J. 2015 Dec;15(6):513-20.  Epub 2015 Mar 17. PubMed PMID: 25778466.

Quantitative Profiling of Human Renal UDP-glucuronosyltransferases and Glucuronidation Activity: A Comparison of Normal and Tumoral Kidney Tissues.
Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C.
Drug Metab Dispos. 2015 Apr;43(4):611-9. Epub 2015 Feb 3. PubMed PMID: 25650382.

The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy.
Laverdière I, Flageole C, Audet-Walsh É, Caron P, Fradet Y, Lacombe L, Lévesque É, Guillemette C.
Endocr Relat Cancer. 2015 Feb;22(1):77-85. Epub 2014 Dec 1. PubMed PMID: 25452636.

Cyclosporin and methotrexate-related pharmacogenomics predictors of acute graft-vs-host disease.
Laverdière I, Guillemette C, Tamouza R, Loiseau P, Peffault de Latour R, Robin M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socié G, Lévesque E.
Haematologica. 2015 Feb;100(2):275-83.  Epub 2014 Nov 25.  Pubmed PMID: 25425682.

Association Between Circulating Levels of Sex Steroid Hormones and Barrett’s Esophagus in Men: a Case-Control Analysis.
Cook MB, Wood SN, Cash BD, Young P, Acosta RD, Falk RT, Pfeiffer RM, Hu N, Su H, Wang L, Wang C, Gherman B, Giffen C, Dykes C, Turcotte V, Caron P, Guillemette C, Dawsey SM, Abnet CC, Hyland PL, Taylor PR.
Clin Gastroenterol Hepatol. 2015 Apr;13(4):673-82.  Epub 2014 Aug 24.  Pubmed PMID: 25158929.

Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.
 Guillemette C, Lévesque E, Rouleau M.
 Clin Pharmacol Ther. 2014 Sep;96(3):324-39. Epub 2014 Jun 12. Pubmed PMID: 24922307.

Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer.
 Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY.
 Int J Cancer. 2014 Dec 1;135(11):2661-7. Epub 2014 Apr 22. Pubmed PMID: 24740842.

Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway. 
Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C.
Clin Cancer Res. 2014 Jun 1;20(11):2971-83. Epub 2014 Mar 28. Pubmed PMID: 24682418.

Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer.
Levesque E, Laverdiere I, Lacombe L, Caron P, Rouleau M, Turcotte V, Tetu B, Fradet Y, Guillemette C.
Clin Cancer Res. 2014 Feb 1;20(3):576-584. Epub 2013 Nov 25. Pubmed PMID: 24277450.

Dual roles for splice variants of the glucuronidation pathway as regulators of cellular metabolism.
Rouleau M, Roberge J, Bellemare J, Guillemette C.
Mol Pharmacol. 2014 Jan;85(1):29-36. Epub 2013 Oct 18. Pubmed PMID: 24141015.

Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer.
Ménard V, Lévesque E, Chen S, Eap O, Joy MS, Ekström L, Rane A, Guillemette C.
Pharmacogenet Genomics. 2013 Dec;23(12):684-96. Pubmed PMID: 24128937.

Modulation of the UGT2B7 enzyme activity by C-terminally truncated proteins derived from alternative splicing.
Ménard V, Collin P, Margaillan G, Guillemette C.
Drug Metab Dispos. 2013 Dec;41(12):2197-205. Epub 2013 Oct 2. Pubmed PMID: 24088326.

Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes.
Ogawa S, Surapisitchat J, Virtanen C, Ogawa M, Niapour M, Sugamori KS, Wang S, Tamblyn L, Guillemette C, Hoffmann E, Zhao B, Strom S, Laposa RR, Tyndale RF, Grant DM, Keller G.
Development. 2013 Aug;140(15):3285-96. Pubmed PMID: 23861064.

Evidence for regulation of UDP-glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in healthy human livers.
Yasar U, Greenblatt DJ, Guillemette C, Court MH.
J Pharm Pharmacol. 2013 Jun;65(6):874-83. Epub 2013 Mar 21. Pubmed PMID: 23647681.

The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure.
Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan SX, Greenblatt DJ, Lee WM; Acute Liver Failure Study Group.
J Pharmacol Exp Ther. 2013 May;345(2):297-307. Epub 2013 Feb 13. PubMed PMID: 23408116.

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Lévesque E, Bélanger AS, Harvey M, Couture F, Jonker D, Innocenti F, Cecchin E, Toffoli G, Guillemette C.
J Pharmacol Exp Ther. 2013 Apr;345(1):95-101. Epub 2013 Feb 5. Pubmed PMID: 23386248.

The relative protein abundance of UGT1A alternative splice variants as a key determinant of glucuronidation activity in vitro.
Rouleau M, Roberge J, Falardeau SA, Villeneuve L, Guillemette C.
Drug Metab Dispos. 2013 Apr;41(4):694-7. Epub 2013 Jan 29. PMID: 23360619.

Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes.
Ekström L, Cevenini L, Michelini E, Schulze J, Thörngren JO, Belanger A, Guillemette C, Garle M, Roda A, Rane A.
Eur J Clin Invest. 2013 Mar;43(3):248-55. Epub 2013 Jan 7. PMID: 23294483.

Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
Lévesque É, Huang SP, Audet-Walsh É, Lacombe L, Bao BY, Fradet Y, Laverdière I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C.
Clin Cancer Res. 2013 Feb 1;19(3):699-709. Epub 2012 Nov 27. PMID: 23186779.

Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia.
Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, Le T, Zehetmayer S, Mannhalter C, Gaiger A, Shehata M, Fleiss K, Skrabs C, Lévesque É, Vanura K, Guillemette C, Jaeger U.
Blood. 2013 Feb 14;121(7):1175-83. Epub 2012 Nov 20. PMID: 23169782.

Protein-protein interactions between the bilirubin-conjugating UDP-glucuronosyltransferase UGT1A1 and its shorter isoform 2 regulatory partner derived from alternative splicing.
Rouleau M, Collin P, Bellemare J, Harvey M, Guillemette C.
Biochem J. 2013 Feb 15;450(1):107-14. PMID: 23148825.

Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
Li J, Menard V, Benish RL, Jurevic RJ, Guillemette C, Stoneking M, Zimmerman PA, Mehlotra RK.
Pharmacogenomics. 2012 Apr;13(5):555-70. PMID: 22462748.

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients.
Laverdière I, Caron P, Couture F, Lévesque E, Guillemette C.
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Feb 15;885-886:131-7. Epub 2012 Jan 9. PMID: 22265668.

The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.
Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque É.
Eur Urol. 2012 Jul;62(1):88-96. Epub 2011 Dec 21. PMID: 22209174.

Liquid chromatography-coupled tandem mass spectrometry based assay to evaluate inosine-5′-monophosphate dehydrogenase activity in peripheral blood mononuclear cells from stem cell transplant recipients.
Laverdière I, Caron P, Couture F, Guillemette C, Lévesque E.
Anal Chem. 2012 Jan 3;84(1):216-23. Epub 2011 Dec 2. PMID: 22092180.

Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants.
Ménard V, Eap O, Roberge J, Harvey M, Lévesque E, Guillemette C.
Pharmacogenet Genomics. 2011 Oct;21(10):631-41. PMID: 21881541.

Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer.
Nadeau G, Bellemare J, Audet-Walsh É, Flageole C, Huang SP, Bao BY, Douville P, Caron P, Fradet Y, Lacombe L, Guillemette C, Lévesque E.
J Clin Endocrinol Metab. 2011 Sep;96(9):E1550-7. Epub 2011 Jul 6. PMID: 21733997.

SRD5A polymorphisms and biochemical failure after radical prostatectomy.
Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E.
Eur Urol. 2011 Dec;60(6):1226-34. Epub 2011 Jun 29. PMID: 21715084.

Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success.
Mehlotra RK, Cheruvu VK, Blood Zikursh MJ, Benish RL, Lederman MM, Salata RA, Gripshover B, McComsey GA, Lisgaris MV, Fulton S, Subauste CS, Jurevic RJ, Guillemette C, Zimmerman PA, Rodriguez B.
J Infect Dis. 2011 Jul 15;204(2):291-8. PMID: 21673041.

Correlation between circulatory, local prostatic, and intra-prostatic androgen levels.
Olsson M, Ekström L, Guillemette C, Belanger A, Rane A, Gustafsson O.
Prostate. 2011 Jun 15;71(9):909-14. Epub 2010 Dec 6. PMID: 21541968.

In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4.
Laverdière I, Caron P, Harvey M, Lévesque É, Guillemette C.
Drug Metab Dispos. 2011 Jul;39(7):1127-30. Epub 2011 Apr 12. PMID: 21487055.

Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5′-diphospho-glucuronosyltransferase (UGT2B17) gene.
Ekström L, Schulze JJ, Guillemette C, Belanger A, Rane A.
Pharmacogenet Genomics. 2011 Jun;21(6):325-32. PMID: 21383644.

Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans.
Bellemare J, Rouleau M, Harvey M, Popa I, Pelletier G, Têtu B, Guillemette C.
J Pathol. 2011 Feb;223(3):425-35. Epub 2010 Oct 29. PMID:21171088.

Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics.
Audet-Walsh E, Lépine J, Grégoire J, Plante M, Caron P, Têtu B, Ayotte P, Brisson J, Villeneuve L, Bélanger A, Guillemette C.
J Clin Endocrinol Metab. 2011 Feb;96(2):E330-9. Epub 2010 Dec 8. PMID: 21147881.

Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
Ting LS, Benoit-Biancamano MO, Bernard O, Riggs KW, Guillemette C, Ensom MH.
Pharmacotherapy. 2010 Nov;30(11):1097-108.

Alternatively spliced products of the UGT1A gene interact with the enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro.
Bellemare J, Rouleau M, Girard H, Harvey M, Guillemette C.
Drug Metab Dispos. 2010 Oct;38(10):1785-9. Epub 2010 Jul 7.

Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways.
Lépine J, Audet-Walsh E, Grégoire J, Têtu B, Plante M, Ménard V, Ayotte P, Brisson J, Caron P, Villeneuve L, Bélanger A, Guillemette C.
J Clin Endocrinol Metab. 2010 Jun;95(6):2689-98. Epub 2010 Apr 6.

Extensive splicing of transcripts encoding the bile acid-conjugating enzyme UGT2B4 modulates glucuronidation.
Lévesque E, Ménard V, Laverdière I, Bellemare J, Barbier O, Girard H, Guillemette C.
Pharmacogenet Genomics. 2010 Mar;20(3):195-210.

Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells.
Bélanger AS, Tojcic J, Harvey M, Guillemette C.
BMC Mol Biol. 2010 Jan 22;11:9.

Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines.
Bellemare J, Rouleau M, Harvey M, Têtu B, Guillemette C.
Pharmacogenomics J. 2010 Oct;10(5):431-41. Epub 2009 Dec 8.

Modulation of the human glucuronosyltransferase UGT1A pathway by splice isoform polypeptides is mediated through protein-protein interactions.
Bellemare J, Rouleau M, Harvey M, Guillemette C.
J Biol Chem. 2010 Feb 5;285(6):3600-7. Epub 2009 Dec 8.

A pharmacogenetics study of the human glucuronosyltransferase UGT1A4.
Benoit-Biancamano MO, Adam JP, Bernard O, Court MH, Leblanc MH, Caron P, Guillemette C.
Pharmacogenet Genomics. 2009 Nov 3. [Epub ahead of print]

The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.
Trottier J, El Husseini D, Perreault M, Pâquet S, Caron P, Bourassa S, Verreault M, Inaba TT, Poirier GG, Bélanger A, Guillemette C, Trauner M, Barbier O.
J Biol Chem. 2010 Jan 8;285(2):1113-21. Epub 2009 Nov 4.

UGT genomic diversity: beyond gene duplication.
Guillemette C, Lévesque E, Harvey M, Bellemare J, Menard V.
Drug Metab Rev. 2010;42(1):22-42. Review.

Ménard V, Eap O, Harvey M, Guillemette C, Lévesque E.
Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism.
Hum Mutat. 2009 Sep;30(9):1310-9.

Bélanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C.
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
Drug Metab Dispos. 2009 Sep;37(9):1793-6.

Ménard V, Girard H, Harvey M, Pérusse L, Guillemette C.Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population.
Hum Mutat. 2009 Apr;30(4):677-87

Benoit-Biancamano MO, Connelly J, Villeneuve L, Caron P, Guillemette C.
Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants.
Drug Metab Dispos. 2009 Feb;37(2):322-9.

Girard H, Butler LM, Villeneuve L, Millikan RC, Sinha R, Sandler RS, Guillemette C. UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans.
Mutat Res. 2008 Sep 26;644(1-2):56-63.

Lévesque E, Benoit-Biancamano MO, Delage R, Couture F, Guillemette C.
Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.
Pharmacogenomics. 2008 Jul;9(7):869-79.

Betônico GN, Abbud-Filho M, Goloni-Bertollo EM, Alvarenga MP, Guillemette C, Villeneuve L, Benoit-Biancamano MO, Pavarino-Bertelli EC.
Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients.
Transplant Proc. 2008 Apr;40(3):708-10.

Girard H*, Lévesque E*, Bellemare J, Journault K, Caillier B, Guillemette C.
Genetic diversity at the UGT1 locus is amplified by a novel 3′ alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity.
Pharmacogenet Genomics. 2007 Dec;17(12):1077-89.

Benoit-Biancamano MO, Caron P, Levesque E, Delage R, Couture F, Guillemette C.
Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):159-67.

Caillier B, Lepine J, Tojcic J, Menard V, Perusse L, Belanger A, Barbier O, Guillemette C.
A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3.
Pharmacogenet Genomics. 2007 Jul;17(7):481-95.

Levesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F,Guillemette C.
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Clin Pharmacol Ther. 2007 Mar;81(3):392-400.

Levesque E, Girard H, Journault K, Lepine J, Guillemette C.
Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a new splicing event at the UGT1A locus.
Hepatology. 2007 Jan;45(1):128-38.

Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C.
Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid.
Drug Metab Dispos. 2006 Sep;34(9):1539-45.

Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C.
The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
Drug Metab Dispos. 2006 Jul;34(7):1220-8.

Thibaudeau J, Lepine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Tetu B, Jacob S, Perusse L, Belanger A, Guillemette C.
Characterization of Common UGT1A8, UGT1A9, and UGT2B7 Variants with Different Capacities to Inactivate Mutagenic 4-Hydroxylated Metabolites of Estradiol and Estrone.
Cancer Res. 2006 Jan 1;66(1):125-133.

Mackenzie PI, Walter Bock K, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW.
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily.
Pharmacogenet Genomics. 2005 Oct;15(10):677-85.

Butler LM, Duguay Y, Millikan RC, Sinha R, Gagne JF, Sandler RS, Guillemette C.
Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer.
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1626-32.

Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C.
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver.
Hepatology. 2005 Aug;42(2):448-57.

Guillemette C, Belanger A, Lepine J.
Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview.
Breast Cancer Res. 2004;6(6):246-54. Epub 2004 Sep 27. Review.

Lepine J, Bernard O, Plante M, Tetu B, Pelletier G, Labrie F, Belanger A, Guillemette C.
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium.
J Clin Endocrinol Metab. 2004 Oct;89(10):5222-32.

Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, Fruchart JC, Guillemette C, Gonzalez FJ, Staels B.
Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha.
Mol Pharmacol. 2005 Jan;67(1):241-9. Epub 2004 Oct 6.

Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C.
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.
Pharmacogenetics. 2004 Aug;14(8):501-15.

Bernard O, Guillemette C.
The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants.
Drug Metab Dispos. 2004 Aug;32(8):775-8.

Duguay Y, Baar C, Skorpen F, Guillemette C.
A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity.
Clin Pharmacol Ther. 2004 Mar;75(3):223-33.

Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, Ritter JK.
Glucuronidation and the UDP-glucuronosyltransferases in health and disease.
Drug Metab Dispos. 2004 Mar;32(3):281-90. Review.

Duguay Y, McGrath M, Lepine J, Gagne JF, Hankinson SE, Colditz GA, Hunter DJ, Plante M, Tetu B, Belanger A, Guillemette C, De Vivo I.
The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk.
Cancer Res. 2004 Feb 1;64(3):1202-7.

Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C.
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
J Pharmacol Exp Ther. 2003 Oct;307(1):117-28. Epub 2003 Aug 27.

Guillemette C.
Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.
Pharmacogenomics J. 2003;3(3):136-58. Review.

Haiman CA, Hankinson SE, De Vivo I, Guillemette C, Ishibe N, Hunter DJ, Byrne C.
Polymorphisms in steroid hormone pathway genes and mammographic density.
Breast Cancer Res Treat. 2003 Jan;77(1):27-36.

Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B.
The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.
J Biol Chem. 2003 Apr 18;278(16):13975-83. Epub 2003 Feb 11.

Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ.
Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9.
Drug Metab Dispos. 2002 Nov;30(11):1257-65.

Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C.
Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Mol Pharmacol. 2002 Sep;62(3):608-17.

Ramirez J, Iyer L, Journault K, Belanger P, Innocenti F, Ratain MJ, Guillemette C.
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
Pharm Res. 2002 May;19(5):588-94.

Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, Lazarus P.
Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes.
Cancer Res. 2002 Apr 1;62(7):1978-86. Erratum in: Cancer Res 2002 Jun 1;62(11):3328.

Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P.
Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk.
J Natl Cancer Inst. 2001 Sep 19;93(18):1411-8.

Guillemette C, De Vivo I, Hankinson SE, Haiman CA, Spiegelman D, Housman DE, Hunter DJ.
Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels.
Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):711-4.

Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE.
Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene.
Pharmacogenetics. 2000 Oct;10(7):629-44.

Woolley AT, Guillemette C, Li Cheung C, Housman DE, Lieber CM.
Direct haplotyping of kilobase-size DNA using carbon nanotube probes.
Nat Biotechnol. 2000 Jul;18(7):760-3.

Guillemette C, Millikan RC, Newman B, Housman DE.
Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans.
Cancer Res. 2000 Feb 15;60(4):950-6.

Hum DW, Belanger A, Levesque E, Barbier O, Beaulieu M, Albert C, Vallee M, Guillemette C, Tchernof A, Turgeon D, Dubois S.
Characterization of UDP-glucuronosyltransferases active on steroid hormones.
J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):413-23. Review.

Belanger A, Hum DW, Beaulieu M, Levesque E, Guillemette C, Tchernof A, Belanger G, Turgeon D, Dubois S.
Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues.
J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):301-10. Review.

Levesque E, Beaulieu M, Guillemette C, Hum DW, Belanger A.
Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line.
Endocrinology. 1998 May;139(5):2375-81.

Levesque E, Beaulieu M, Guillemette C, Hum DW, Belanger A.
Effect of fibroblastic growth factors (FGF) on steroid UDP-glucuronosyltransferase expression and activity in the LNCaP cell line.
J Steroid Biochem Mol Biol. 1998 Jan;64(1-2):43-8.

Guillemette C, Levesque E, Beaulieu M, Turgeon D, Hum DW, Belanger A.
Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells.
Endocrinology. 1997 Jul;138(7):2998-3005.

Guillemette C, Hum DW, Belanger A.
Regulation of steroid glucuronosyltransferase activities and transcripts by androgen in the human prostatic cancer LNCaP cell line.
Endocrinology. 1996 Jul;137(7):2872-9.

Guillemette C, Hum DW, Belanger A.
Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP.
J Steroid Biochem Mol Biol. 1996 Feb;57(3-4):225-31.

Guillemette C, Hum DW, Belanger A.
Specificity of glucuronosyltransferase activity in the human cancer cell line LNCaP, evidence for the presence of at least two glucuronosyltransferase enzymes.
J Steroid Biochem Mol Biol. 1995 Dec;55(3-4):355-62.

Belanger G, Beaulieu M, Marcotte B, Levesque E, Guillemette C, Hum DW, Belanger A.
Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line.
Mol Cell Endocrinol. 1995 Sep 22;113(2):165-73.

Guillemette C, Belanger A.
Glucuronosyltransferase activity in human cancer cell line LNCaP.
Mol Cell Endocrinol. 1995 Feb;107(2):131-9.

Book chapters

David P. Josephy
Molecular Toxicology : Contribution to the chapter « The glucuronidation pathway »
To be published in 2006